clinical trial · NCT06592794
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc.·phase3·active not recruiting·n = 37,864
Acute GastroenteritisNorovirus Acute GastroenteritismRNA-1403Placebo
brief summary
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
started
Sep 24, 2024
primary completion
Feb 15, 2027
completion
Feb 15, 2027
last updated
Feb 25, 2026
official title
A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol